- Home
- BFRI vs BOLT Comparison
BFRI vs BOLT Comparison
Compare BFRI & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | BOLT |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | 93 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BFRI | BOLT |
|---|---|---|
| Price | $0.81 | $4.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.75 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 104.5K | 16.5K |
| Earning Date | 03-19-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $19.80 | $56.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.54 | $0.26 |
| 52 Week High | $1.18 | $7.35 |
Technical Indicators
Market Signals| Indicator | BFRI | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 44.85 |
| Support Level | $0.80 | $3.91 |
| Resistance Level | $0.89 | $5.36 |
| Average True Range (ATR) | 0.05 | 0.32 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 23.76 | 47.50 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.